Ann Arthritis Clin Rheumatol | Volume 4, Issue 1 | Case Report | Open Access

Overlap Syndrome: Dermatomyositis and Systemic Lupus Erythematosus with Cerebral Lupus and Autoimmune Hepatitis: A Case Report

Sulaiman W1,2*, Subramaniam R1, Sarkan MM2 and Samhari AA3

1Universiti Kuala Lumpur Royal College of Medicine, Malaysia
2Perak Community Specialist Hospital, Malaysia
3Bone and Joint Specialist, Pusat Bandar Seberang Jaya, 13600, Seberang Perai, Malaysia
4Department of Dermatology, Raja Permaisuri Bainun Hospital, Ipoh, Malaysia

*Correspondance to: [email protected] 

Fulltext PDF

Abstract

Dermatomyositis (DM), a rare autoimmune disorder, is a subtype of Idiopathic Inflammatory Myositis (IIM) characterized by classical cutaneous lesions with increased muscle enzyme creatinine kinase. DM has been reported to overlap with other rheumatic diseases, mainly with systemic sclerosis. Data of coexistence of DM and Systemic Lupus Erythematosus (SLE) was however limited. Herein, we described a young girl with overlap severe DM and SLE with mixed cutaneous lesions complicated by lupus cerebritis and hepatitis. The patient fulfilled the American College Rheumatology (ACR) Classification Criteria for SLE 2012 and Systemic Lupus International Collaboration Clinics (SLICC) 2012, and Bohan and Peter criteria for DM. Patient was given the combination treatment of corticosteroid and immunosuppressant and responded well. Our case reported highlighted the rare and complicated overlap autoimmune disorders of DM and SLE, which is yet to be reported in our region. Our case report may help aid early recognition of the overlapping of DM and SLE may provide useful information for a future encounter.

Keywords:

Dermatomyositis; Systemic Lupus Erythematosus; Overlap syndrome; Lupus cerebritis; Hepatitis

Citation:

Sulaiman W, Subramaniam R, Sarkan MM, Samhari AA. Overlap Syndrome: Dermatomyositis and Systemic Lupus Erythematosus with Cerebral Lupus and Autoimmune Hepatitis: A Case Report. Ann Arthritis Clin Rheumatol. 2021; 4(1): 1023..

Subscribe to Our Newsletter